Overview
Pharmaceutical firm's Q4 revenue rose 10%
Adjusted EPS for Q4 beat analyst expectations
Company provides 2026 adjusted EPS guidance of $14.37 to $14.57
Outlook
AbbVie issues 2026 adjusted diluted EPS guidance of $14.37 to $14.57
Company expects robust growth in 2026 driven by strong fundamentals
Result Drivers
IMMUNOLOGY GROWTH - AbbVie reported a significant increase in immunology portfolio revenues, driven by Skyrizi and Rinvoq, which grew by 32.5% and 29.5% respectively
NEUROSCIENCE PERFORMANCE - Neuroscience portfolio revenues rose by 17.9%, with notable contributions from Vraylar and Qulipta
ONCOLOGY CHALLENGES - Oncology portfolio faced a decline in Imbruvica revenues, which decreased by 20.8%
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $16.62 bln | $16.42 bln (20 Analysts) |
Q4 Adjusted EPS | Beat | $2.71 | $2.65 (18 Analysts) |
Q4 EPS | $1.02 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for AbbVie Inc is $245.00, about 8.6% above its February 3 closing price of $225.66
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 16 three months ago
Press Release: ID:nPn2rBnnla
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)